RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro

Blood

Volumn 106, Issue 9, 2005, Pages 3134-3141

  Ohtsuka, Yoshitoshi ^b   Manabe, Atsushi ^b   Kawasaki, Hirohide ^b   Hasegawa, Daisuke ^b   Zaike, Yuji ^b   Watanabe, Sumiko ^b   Tanizawa, Takakuni ^b   Nakahata, Tatsutoshi ^b   Tsuji, Kohichiro ^a  

^a THE UNIVERSITY OF TOKYO   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CELL CLONE; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; COLONY FORMING UNIT; COLONY FORMING UNIT GM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOCHEMISTRY; DRUG ACTIVITY; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INFANT; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKEMIA CELL; MACROPHAGE; MALE; MONOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; SUSPENSION CELL CULTURE;

EID: 27644504641     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-03-0972     Document Type: Article

References (40)

1. Niemyer CM, Arico M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: a report of 110 cases. Blood. 1997;89:3534-3543.
2. Emanuel PD. Myelodysplastic and myeloproliferative disorders in childhood: an update. Br J Haematol. 1999;105:852-863.
3. Arico M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood. 1997;90:479-488.
4. Passmore SJ, Hann IM, Stiller CA, et al. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring systems. Blood. 1995;85:1742-1750.
5. Manabe A, Okamura J, Yumura-Yagi K, et al. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the international JMML Working Group. Leukemia. 2002;16:645-649.
6. Lutz P, Zix-Kieffer I, Souillet G, et al. Juvenile myelomonocytic leukemia: analysis of treatment results in the EORTC children's leukemia cooperative group (CLCG). Bone Marrow Transplant. 1996;18:1111-1116.
7. Locatelli F, Nöllke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood. 2005;105:410-419.
8. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zukerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 1991;77:925-929.
9. Suda J, Eguchi M, Akiyama Y, et al. Differentiation of blast cells from Down Syndrome patient with transient myeloproliferative disorder. Blood. 1987;69:508-512.
10. Tartaglia M, Niemyer CM, Song X, et al. Somatic PTPN11 mutations in juvenile myelomonocytic leukemia, myelodysplastic syndromes, and acute myeloid leukemia. Nat Genet. 2003;34:148-150.
11. Flotho C, Valcamonica S, Mach-Pascula S, et al. Ras mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia. 1999;13:32-37.
12. Sheng XM, Kawamura M, Ohnishi H, et al. Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile myelomonocytic leukemia. Leukemia Res. 1997;21:697-701.
13. Miyauchi J, Asada M, Sasaki M, et al. Mutations of the N-ras genes in juvenile chronic myelogenous leukemia. Blood. 1994;83:2248-2254.
14. Kalra R, Padermura DC, Olson K, Shannon KM. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood. 1994;84:3435-3439.
15. Side LE, Emanuel PD, Taylor B, et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type1. Blood. 1998;92:267-272.
16. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29:465-468.
17. Iverson PO, Rodwell RL, Pitcher L, Taylor KM, Lopez AF. Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by granulocyte-macrophage colony-stimulating factor analogue E21R. Blood. 1996;88:2634-2639.
18. Iverson PO, Lewis ID, Turczynowicz S, et al. Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice. Blood. 1997;90:4910-4917.
19. Willumsen BM, Norris K, Papageorge AG, Hubbert NL, Lowy DR. Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of cysteine nearest the carboxy terminus. EMBO J. 1984;3:2581-2585.
20. Rowinski EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999;17:3631-3652.
21. Jackson JH, Cochrane CG, Bourne JR, et al. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad U S A. 1990;87:3042-3046.
22. Peters DG, Hoover RR, Gerlach MJ, et al. Activity of farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404-1412.
23. Emanuel PD, Richard C, Wiley ST, Gopurala B, Castleberry RP. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood. 2000;95:639-645.
24. Whyte DB, Kischmeier P, Hockenberry TN, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 1997;272:14459-14464.
25. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001;84:1126-1134.
26. Berenson J, Ravera C, Ma P, et al. Population pharmacokinetics of zometa [abstract]. Proc Am Soc Clin Oncol. 2002;21:209a.
27. Green JR. Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin Oncol. 2001;84:1126-1134.
28. Pinkel D, Aricó M, Biondi A, et al. Differentiating juvenile myelomonocytic leukemia from infectious disease [letter]. Blood. 1998;91:365-367.
29. Ebihara Y, Tsuji K, Lyman SD, et al. Synergistic action of Flt3 and gp130 signalings in human hematopoiesis. Blood. 1997;90:4363-4368.
30. Nishijima I, Nakahata T, Watanabe S, et al. Hematopoietic and lymphopoietic responses in human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor transgenic mice injected with human GM-CSF. Blood. 1997;90:1031-1038.
31. Nakahata T, Ogawa M. Hematopoietic colonyforming cells in umbilical cord blood with extensive capability to generate mono- and multipotential hematopoietic progenitors. J Clin Invest. 1982;70:1324-1328.
32. Sui X, Tsuji K, Tanaka R, et al. gp130 and c-Kit signalings synergize for ex vivo expansion of human primitive hematopoietic progenitor cells. Proc Natl Acad Sci U S A. 1995;92:2859-2863.
33. Ueda T, Tsuji K, Yoshino H, et al. Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor. J Clin Invest. 2000;105:1013-1021.
34. + cells. J Exp Med. 1996;184:1357-1364.
35. Stelzer GT, Shults KE, Loken MR. CD45 gating for routine flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Ann N Y Acad Sci. 1993;677:265-280.
36. Estrov Z, Grunberger T, Cahn HSL, Freedman MH. Juvenile chronic myelogenous leukemia: characterization of the disease using cell cultures. Blood. 1986;67:1382-1387.
37. Hibi S, Lohler J, Friel J, Stocking C, Ostertag W. Induction of monocytic differentiation and tumorigenicity by v-Ha-ras in differentiation-arrested hematopoietic cells. Blood. 1993;81:1841-1848.
38. Darley RL, Burnett AK. Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors. Exp Hematol. 1999;27:1599-1608.
39. Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42:1228-1236.
40. + leukemia activity of imatinib mesylate. Blood. 2003;102:2229-2235.